Brief: Acorda Therapeutics Reports Second Quarter 2022 Financial Results
04/08/2022 21:51
Aug 4 (Reuters) - Acorda Therapeutics Inc ACOR.O :
* ACORDA THERAPEUTICS REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS
* Q2 NON-GAAP LOSS PER SHARE $3.15
* Q2 GAAP LOSS PER SHARE $2.78
* FOR FULL YEAR 2022, ACORDA CONTINUES TO EXPECT AMPYRA NET REVENUE TO BE
$68 -
$78 MILLION
Source text for Eikon: ID:nBw62jv2xa
Further company coverage: ACOR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Acorda Therapeutics
See all newsBrief: Acorda TherapeuticsCourt Held Hearing To Consider Approval Of Sale Of Substantially All Of Co's Assets To Merz Pharmaceuticals Under Asset Sale
Brief: Acorda Says Debtors Did Not Receive More Than One Qualified Bid Before Bid Deadline, In Connection With Chapter 11 Proceedings
Live Markets: Biotech companies in 'Darwinian' world as cash remains king
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease (updated)
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease